Lumos Change In Working Capital from 2010 to 2024

LUMO Stock  USD 4.30  0.01  0.23%   
Lumos Pharma Change In Working Capital yearly trend continues to be very stable with very little volatility. Change In Working Capital is likely to grow to about 1 M this year. Change In Working Capital is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. View All Fundamentals
 
Change In Working Capital  
First Reported
2009-12-31
Previous Quarter
782 K
Current Value
2.3 M
Quarterly Volatility
4.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
  
Check out the analysis of Lumos Pharma Correlation against competitors.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Latest Lumos Pharma's Change In Working Capital Growth Pattern

Below is the plot of the Change In Working Capital of Lumos Pharma over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. Lumos Pharma's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
Change In Working Capital10 Years Trend
Pretty Stable
   Change In Working Capital   
       Timeline  

Lumos Change In Working Capital Regression Statistics

Arithmetic Mean(236,650)
Geometric Mean1,490,978
Coefficient Of Variation(1,097)
Mean Deviation2,138,593
Median(163,000)
Standard Deviation2,595,345
Sample Variance6.7T
Range8.2M
R-Value0.13
Mean Square Error7.1T
R-Squared0.02
Significance0.65
Slope74,963
Total Sum of Squares94.3T

Lumos Change In Working Capital History

2024M
2023965 K
20222.1 M
2021-2.3 M
2020-3.6 M
20194.6 M
2018-2.7 M

About Lumos Pharma Financial Statements

Lumos Pharma investors utilize fundamental indicators, such as Change In Working Capital, to predict how Lumos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Working Capital965 KM
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:
Check out the analysis of Lumos Pharma Correlation against competitors.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
0.27
Quarterly Revenue Growth
102.714
Return On Assets
(0.70)
Return On Equity
(1.73)
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.